Year: 2020
Type: article
Abstract: Background Dr. Bateman is principal investigator of a therapeutic trial evaluating two investigational drugs, gantenerumab and solanezumab, for dominantly inherited Alzheimer’s disease. Washington University is also the regulatory sponsor for this trial. Funding for DIAN‐TU clinical trials includes the National Institute on Aging of the National Institutes of Health, Alzheimer's Association, Eli Lilly and Co, Hoffman La‐Roche/Genentech, Janssen, Avid Radiopharmaceuticals, GHR Foundation, and an anonymous foundation. Discussion session with leaders from the collaborative group: Randall Bateman (DIAN‐TU, PI), Laurie Ryan (NIH/NIA), Maria Carrillo (Alzheimer’s Association), John Sims (Eli Lilly and Co.), Geoff Kerchner (F. Hoffman‐La‐Roche, Ltd.), Marty Farlow (DIAN‐TU Project Arm Leader, Sola), and Steve Salloway (DIAN‐TU Project Arm Leader, Gant). Trial results discussed.
Source: Alzheimer s & Dementia
DOI: 10.1002/alz.041133
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3110769894